FDA Toots Its Own Horn On Safety Of Marketed Drugs, Imports
This article was originally published in The Tan Sheet
FDA’s Global Engagement report describes the agency’s actions to protect the international supply chain. Meanwhile, the Advances in FDA’s Safety Program for Marketed Drugs report notes label changes and safety studies mandated under its post-market drug safety program.
You may also be interested in...
FDA warns consumers of link between PPIs and clostridium difficile-associated diarrhea; FDA commissioner adopts transparency proposals; Wholistic Herbs herbal eye and nasal sprays on recall; more Regulatory News In Brief.
FDA seeks new authority over the international drug supply chain to support a global safety plan.
FDA expects to accomplish the goals of its Safe Use Initiative through a combination of voluntary moves by industry and regulatory activities